AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 271 min read$MEDP

Troendle August J. sold $2.9M of MEDP

Troendle August J. (President & CEO) sold 4,673 shares of Medpace Holdings, Inc. (MEDP) at an average of $620.08 ($620.03–$620.38, $2.90M total) across 2 trades over 2026-08-25 to 2026-08-26.

Original reporting
SEC EDGAR · Troendle August J.
Published Aug 27, 2026, 8:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MEDP
Bearish
medium confidence
Mentioned
$MEDP
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDPBearishLow
01

Why it matters

Insider sale may signal reduced confidence, potentially pressuring the stock short-term.

02

Market read

Insider sales are monitored by traders for potential signals about company outlook.

03

Timing

post-market 2026-08-27

Relevance 6/10Novelty 6/10Timing: post-market 2026-08-27

Background

Form 4 filing discloses insider transaction by Medpace CEO.

Company-level read

Ticker impact

$MEDPBearishMedium confidence
Context

President & CEO Troendle August J. sold 4,673 shares for $2.9M, reducing his stake to 540,544 shares.

Expected impact

Modest downside pressure over the next few days.

Evidence & confidence

The sale size is modest relative to holdings but represents a $2.9M cash outflow by the CEO.

Key entities

  • company
    Medpace Holdings, Inc.

    Clinical research organization listed on NASDAQ (MEDP).

  • person
    Troendle August J.

    President & CEO of Medpace.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MEDP insider trading history →

Related articles

JUL 24
$ADVBMed

Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.

rttnews.com7 min